Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
Cat.No. : CSC-RO0181 Host Cell: SH-SY5Y
Size: >1x10^6 cells/vial Validation: T7 Endonuclease I assay
| Cat. No. | CSC-RO0181 |
| Description | SH-SY5Y-Cas9 cell line is engineered to stably overexpress Cas9 nuclease. The Cas9 nuclease in SH-SY5Y-Cas9 cell line has been functionally validated using T7 Endonuclease I assay. In combination with separately transfected sgRNAs, SH-SY5Y-Cas9 cell line can be used to efficiently generate targeted genomic modifications including gene knockout, gene knockin, gene mutagenesis, gene tagging etc. It is also an ideal cell line model for sgRNA screening and validation, either individually or in pools. |
| Introduction | Clustered regularly interspaced palindromic repeats (CRISPR)/Cas9 is a gene-editing technology that contains two essential components: a guide RNA (gRNA) to match a target gene, and the Cas9 (CRISPR-associated protein 9) endonuclease which causes a double-stranded DNA break, allowing modifications to the genome via nonhomologous end joining (NHEJ) or homology-directed repair (HDR). |
| Target Gene | Cas9 |
| Host Cell | SH-SY5Y |
| Host Cell Species | Homo sapiens (Human) |
| Product Type | Cas9 overexpression stable cell line |
| Applications | 1) CRISPR genome editing, such as gene knockout (KO), gene knockin (KI), gene mutagenesis, gene tagging etc. 2) High-throughput sgRNA screening and validation |
| Quality Control | 1) T7E1 assay 2) Mycoplasma detection |
| Size Form | One vial of frozen cells, typically >1x10^6 cells/vial |
| Shipping | Dry ice |
| Storage | Liquid nitrogen |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
Researchers employed CRISPR‐Cas9 technology to investigate the impact of a rare mutation (rs144662445) in the AKAP9 gene, linked to Alzheimer's disease (AD) in African Americans (AA), on tau pathology and the tau interactome in SH‐SY5Y P301L neuron‐like cells. The mutation notably elevated phosphorylated tau levels, particularly at Ser396/Ser404. Additionally, analysis of the tau interactome revealed dysregulation of RNA translation, localization, and oxidative activity, resembling findings from human AD brain samples. Functional assays confirmed reduced protein synthesis and increased oxidative stress, mimicking AD pathology. These findings highlight the role of AKAP9 in AD pathogenesis.
Figure 1. CRISPR-mediated AKAP9 I2558M mutation knock-in was performed in SH-SY5Y P301L cells, followed by neuronal differentiation. Mutation generation was confirmed by Sanger sequencing. (You Y, et al., 2022)
Creative Biogene's Cas9 Stable Cell Line-SH-SY5Y expedites similar studies, eliminating the need for gene editing steps. This pre-engineered cell line directly investigates gene mutation effects on tau pathology and the tau interactome, saving time and costs while accelerating disease mechanism understanding.
A: BXPC-3 cells were likely selected for their relevance to pancreatic cancer research and their ability to be efficiently edited using CRISPR/Cas9 technology, enabling studies on gene function and therapeutic targets.
A: Efficiency and specificity were likely assessed through methods such as genomic sequencing, functional assays measuring indel formation, or reporter assays targeting known Cas9 cleavage sites.
A: Characterization may involve analysis of knockout or knock-in efficiency, off-target effects, changes in cellular proliferation, migration, or response to chemotherapeutic agents upon genetic manipulation.
A: Quality control likely included confirmation of Cas9 expression levels, validation of its editing efficiency and specificity, assessment of off-target effects, and validation of phenotypic changes associated with genetic manipulation.
A: Comparative analysis with other pancreatic cancer models or patient-derived samples helps elucidate the functional significance of targeted genes, identify novel therapeutic targets, and guide personalized treatment strategies for pancreatic cancer patients.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
Outstanding versatility! The Cas9 Stable Cell Line in SH-SY5Y cells has been a versatile tool in our neurobiology research. Its stable expression of Cas9 has enabled precise and efficient genome editing, facilitating the investigation of neuronal gene function and regulation.
United States
11/13/2022
Reliable and efficient! The stable expression of Cas9 in SH-SY5Y cells has allowed us to perform targeted gene editing with high specificity and efficacy. Its consistent Cas9 expression has ensured reliable and reproducible results across experiments, enhancing the robustness of our findings.
United Kingdom
05/22/2022
Simplifying our studies! With the Cas9 Stable Cell Line, we've been able to explore the molecular mechanisms underlying neurological disorders with confidence. Its stable expression of Cas9 has simplified experimental workflows and accelerated the pace of our research.
Canada
01/26/2022
Impressive performance! The Cas9 Stable Cell Line has consistently exhibited efficient Cas9-mediated genome editing, surpassing our expectations. Its stable expression has been pivotal in uncovering the genetic basis of neurodevelopmental and neurodegenerative diseases.
French
03/24/2023
A valuable asset in neuroscience! The Cas9 Stable Cell Line has revolutionized our approach to studying brain function and dysfunction. Its stable expression of Cas9 has provided a reliable platform for dissecting the complexities of neuronal biology and identifying potential therapeutic targets.
Canada
03/08/2023
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.